Tvardi Therapeutics (TVRD) Earnings Date & Reports

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

TVRD is expected to report earnings to fall 19.07% to -55 cents per share on November 12

Tvardi Therapeutics TVRD Stock Earnings Reports

Q3'26

Est.

$-0.56

Q2'26

Beat

by $0.01

Q1'26

Missed

by $0.18

Q4'25

Missed

by $0.58

Q3'25

Missed

by $0.36

The last earnings report on August 14 showed earnings per share of -68 cents, beating the estimate of -69 cents. With 62.60K shares outstanding, the current market capitalization sits at 24.88M.

View a ticker or compare two or three

TVRD

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for TVRD